Background
Adult neurogenesis appears to be restricted to two regions, i.e., the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG). Importantly, adult hippocampal neurogenesis (AHN) was first reported over 50 years ago by Altman and Das [
1], and newborn neurons are generated continuously throughout life in the mammalian brain, including the human brain [
2,
3]. Since then, numerous studies have reported that AHN is implicated in cognition and endogenous repair mechanisms in normal physiological conditions such as learning and memory [
4]. Interestingly, according to the recent research, the persistence of AHN appears to be decreased in aged adults and Alzheimer’s disease (AD) [
5,
6].
AD is one of the major causes of age-related dementia and is characterized by cognitive impairment, amyloid-β deposition in plaques, tau hyperphosphorylation in neurofibrillary tangles, loss of synapses, loss of neuronal cells, and cholinergic dysfunction [
7]. Dysfunction of the basal forebrain cholinergic (BFC) system, a significant characteristic of AD, induces neuropathological changes before clinical symptoms manifest [
8‐
10]. The hippocampus and cortex receive gamma-aminobutyric acidergic, glutamatergic, and cholinergic input from the basal forebrain of the medial septum-diagonal band complex (MS/DB) [
11,
12]. Thus, lesions in, or the inactivation of, cholinergic neurons in MS/DB result in a decrease of acetylcholinesterase (AChE) and choline acetyltransferase (ChAT), consequently diminishing AHN [
13‐
16].
Despite intensive research efforts, none of the currently available treatments for AD can completely cure or prevent the course of age-related cognitive impairment, and the pathological mechanism is not clearly understood. Numerous pharmacological therapies have been developed to treat AD [
17]. However, 98% of small-molecule drugs (< 400 Da) and 100% of large-molecule drugs (> 500 Da) cannot cross the blood-brain barrier (BBB) [
18], making the prevention and treatment of brain disorders difficult.
Focused ultrasound (FUS) combined with contrast agent microbubbles is a noninvasive technique that transiently opens BBB in targeted regions, thereby enabling localized therapeutic drug, gene, or nanoparticle delivery into the brain for treating central nervous system (CNS) disorders [
19‐
21]. Considering that drugs that have been, or are currently being, developed for AD are mostly large molecules, FUS may enhance the effects of these drugs especially in patients with early-stage AD who have an intact BBB [
22]. Moreover, several reports suggest that FUS stimulates neuronal activity and modulates proteomes and transcriptomes, independent of any therapeutic agent [
23‐
25].
Previous studies indicate that FUS-mediated BBB opening can modulate the accumulation of amyloid-β and tau hyperphosphorylation in AD transgenic mice and increase AHN in wild-type mice [
26‐
30]. Recently, Moreno-Jiménez et al. reported the persistence of AHN in human DG of subjects aged over 90 years; however, the number and maturation of immature neurons in DG sharply decreased in patients with AD. This finding has gained attention for potential therapeutic strategies as an underlying memory impairment in AD [
31]. However, it remains unclear whether FUS can modulate AHN in a cholinergic-deficient condition. In this study, we investigated the effect of FUS on AHN and the cholinergic system in a cholinergic degeneration dementia rat model, which is a key pathogenic feature of dementia. Furthermore, if FUS was effective in increasing AHN, the synergistic effects of AHN modulation and drug delivery could improve treatment outcomes of AD.
Discussion
Although FUS may remedy the impermeability of BBB to pharmacotherapy, the effects of FUS on cholinergic function and AHN have not been elucidated in cholinergic-deficient conditions. Cholinergic systems regulate memory processing and cognitive function and link the memory circuit constituted by FC, hippocampus, and MS [
40,
41]. The present study was designed to measure and analyze the potential effects of FUS in a rat model of dementia mimicking the BFC depletion in AD. The cholinergic dysfunction in this model was induced by intraventricular injection of SAP. This immunotoxin acts by coupling the ribosome-inactivating protein to a monoclonal antibody, which has a low affinity for the nerve growth factor receptor p75, located on BFC neuron bodies [
42,
43]. In this study, we examined the cholinergic degeneration in this model, and our results revealed that the number of ChAT neurons was significantly reduced in MS of the SAP and SAP+FUS groups both 5 days and 18 days after FUS (Fig.
2), which proves that cholinergic dysfunction was well-established in this rat model, and the results are consistent with our previous results [
33‐
36,
44,
45].
Because the reduction in AChE activity by cholinergic lesions in the hippocampus is closely correlated with Ach and AChE following compensatory mechanisms induced by SAP, we observed AChE activity in FC and the hippocampus [
46] to examine the effects of FUS. Interestingly, the FUS group also exhibited decreases in the activity at 24 h, suggesting that sonication did not acutely affect AChE activity at 24 h (Fig.
3a, b). However, the SAP+FUS group showed a significantly increased AChE activity in the hippocampus 18 days after sonication (Fig.
3c, d), which implies that the FUS-mediated BBB opening resulted in the recovery of AChE levels.
EGR1 can activate AChE gene expression by binding to the AChE promoter. Overexpression of acetylcholine and AChE is critical for upregulating proliferative activity and subsequent neurogenesis [
46]. Furthermore, acetylcholine modulates hippocampal long-term potentiation (LTP), thereby stimulating cholinergic neurons and enhancing hippocampal LTP [
47,
48]. Another factor contributing to neurogenesis is BDNF, which has gained attention for its role in the regulation of synaptic transmission and plasticity, and neural circuit function in the CNS [
49]. An insufficient supply of endogenous BDNF leads to neurodegeneration, cognitive impairment, and sharp decreases in neuronal proliferation in SGZ [
50,
51]. Furthermore, dysfunction in the cholinergic forebrain system diminishes AHN in DG [
52]. FUS increases neurogenesis in wild-type mice [
29], and the effect of BDNF endures even 24 h after FUS treatment [
24]. Because the correlation between BDNF and AHN has been already proven in previous research [
53], our goal was to observe changes in BDNF and EGR1 activities in this model and how those factors could recover via FUS.
Consistent with previous observations, we demonstrated that the cholinergic-deficient conditions in the SAP group significantly reduced BDNF expression levels in the hippocampus (Fig.
3e, f) [
54,
55]. The present study further demonstrated that the FUS-mediated BBB opening elevated BDNF expression both 24 h and 18 days after sonication of the hippocampus (Fig.
3f–h) and improved neurogenesis in GCL/SGZ of DG (Fig.
5d). These results indicate that FUS can promote BDNF expression 24 h after sonication, thereby confirming the results of previous research [
24]. The mature BDNF primarily binds to the TrkB receptor, which plays a role in the development, maintenance, and differentiation of neurons and cell survival [
56‐
58]. The maintenance of elevated expression of BDNF 18 days after sonication suggests that BDNF continuously regulates neurogenesis, synaptic plasticity, and membrane excitability [
59,
60]. Our results indicate that diminished cholinergic input to the hippocampus reduces BDNF expression; FUS-mediated opening of BBB reverses these effects by stimulating hippocampal BDNF expression, which consequently regulates AHN positively in cholinergic degeneration [
4].
Compared with the control group, the SAP group displayed decreased levels of EGR1 in the hippocampus (Fig.
4a), whereas EGR1 activity in the FUS group was significantly increased compared with that in the SAP group. Prior evidence has demonstrated that extracellular BDNF activates ERK expression by TrkB neurotrophin receptor [
61]. The activation of transcription factors, such as CREB and IEGs including
c-fos and
Egr1, is followed by increased ERK phosphorylation [
62]. This activation may play a critical role in BDNF upregulation induced by FUS, which could potentially contribute to the upregulation of EGR1 (Fig.
4a). In many studies, EGR1 transcription factors have been demonstrated to be major regulators and mediators of synaptic activity and plasticity under certain physiological conditions [
63,
64]. Thus, our findings support prior evidence that BDNF facilitates the return of EGR1 to normal levels.
Our data support the theory that forebrain acetylcholine affects AHN, and a selective cholinergic lesion of the BFC system induces a decrease in BrdU, EGR1, DCX, and AChE levels; therefore, these findings indicate a reduction in proliferation and neuroblast production in SGZ and a decrease in hippocampal acetylcholine activity, respectively [
35]. We found that the FUS-mediated BBB opening led to an increase in BDNF, EGR1, and AHN levels, which lead to an improvement in cognitive function.
Based on results from the behavioral test, we could also confirm that FUS enhanced memory and cognitive function. The performance of all rats in all groups gradually improved across 5 days of MWM training, suggesting that rats with cholinergic dysfunction have a similar level of learning capacity and escape latency compared with wild-type rats (Fig.
6) [
34,
35]. In the probe test, when compared with the control and FUS groups, the SAP group displayed a diminished MWM performance 72 h after final training, as measured by the number of crossing over the platform area and time spent, which complements the findings of previous studies [
33‐
36,
44]. However, FUS improved spatial memory, and cognition correlated with increases in EGR1, BDNF, and AHN. According to a recent study, increases in both AHN and BDNF levels affected memory improvement, similar to the effects of exercise in AD transgenic mouse [
65]. However, increases in AHN alone did not have any effect [
65]. Significant differences in speed were not observed among the groups, suggesting that there are no SAP-induced differences in motor function (Fig.
6e), which is consistent with our previous findings [
35].
Although the data herein showed remarkable effects of FUS in this rat model, this study has several limitations that should be addressed in future research. We fixed sonication parameters to induce 0.25 MPa of acoustic pressure, which was adopted from our previous study [
66]. However, recent studies have used an acoustic feedback system based on the passive cavitation detector to prevent tissue damage. This technique may guarantee appropriate sonication power and could be suitable for clinical application. Our previous study demonstrated that a FUS-mediated BBB opening could be safely and effectively performed within certain parameters [
66]. Moreover, we used MRI to confirm BBB opening (T1W) without cell edema (T2W) after sonication (Fig.
1e, f). Furthermore, we observed increased BDNF expression only at 24 h and 18 days after sonication so different time points between 24 h and 18 days could be further studied to assess the changes in BDNF. In addition, we observed the recovery effects of FUS on EGR1 activities at 5 days in the model; thus, based on these results, we could assume that neuroblast production and cell migration might have maintained [
53]. We could anticipate LTP and synaptic strength would recover.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.